A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma.
Mehta Vedant KamalMahadev RaoRama Rao DamerlaAnanth PaiKrishan SharanAkhil PalodPreethi S ShettyNawaz UsmanNaveena Kumar AnPublished in: Cancer investigation (2022)
The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies.
Keyphrases
- low dose
- high dose
- immune response
- locally advanced
- signaling pathway
- rectal cancer
- poor prognosis
- human health
- palliative care
- squamous cell carcinoma
- density functional theory
- vascular endothelial growth factor
- stem cells
- dendritic cells
- risk assessment
- combination therapy
- replacement therapy
- long non coding rna
- molecular dynamics
- wound healing
- cell therapy
- childhood cancer